Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7% – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was down 3.7% during trading on Wednesday . The company traded as low as $13.71 and last traded at $14.65. Approximately 1,371,627 shares traded hands during trading, an increase of 16% from the average daily volume of 1,180,047 shares. The stock had previously closed at $15.21.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research note on Sunday. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Trading Down 3.3 %

The firm has a market cap of $2.75 billion, a PE ratio of -0.28 and a beta of 2.07. The firm has a fifty day simple moving average of $0.30 and a two-hundred day simple moving average of $0.27. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.